{"name":"Astellas Venture Management","permalink":"astellas-venture-management","crunchbase_url":"http://www.crunchbase.com/financial-organization/astellas-venture-management","homepage_url":"http://www.astellasventure.com","blog_url":"","blog_feed_url":"","twitter_username":"","phone_number":"","description":"","email_address":"","number_of_employees":null,"founded_year":2005,"founded_month":9,"founded_day":22,"tag_list":null,"alias_list":"","created_at":"Thu Jun 04 10:03:23 UTC 2009","updated_at":"Thu Jun 11 12:34:40 UTC 2009","overview":"<p>Astellas Venture Management is a financial organisation which targets its investments in the biotechnologies. They invest in companies that are dedicated to developing new pharmaceutical seeds, or constructing a new drug discovery platform. Their investments are not limited to any geographical location.</p>","image":{"available_sizes":[[[150,23],"assets/images/resized/0004/6637/46637v1-max-150x150.png"],[[250,39],"assets/images/resized/0004/6637/46637v1-max-250x250.png"],[[450,71],"assets/images/resized/0004/6637/46637v1-max-450x450.png"]],"attribution":null},"offices":[{"description":"","address1":"","address2":"","zip_code":"","city":"Menl","state_code":"CA","country_code":"USA","latitude":null,"longitude":null}],"relationships":[],"investments":[{"funding_round":{"round_code":"b","source_url":"","source_description":"Capital Funding Report","raised_amount":22000000,"raised_currency_code":"USD","funded_year":2008,"funded_month":6,"funded_day":2,"company":{"name":"Inimex Pharmaceuticals","permalink":"inimex-pharmaceuticals","image":{"available_sizes":[[[125,46],"assets/images/resized/0004/6632/46632v1-max-150x150.jpg"],[[125,46],"assets/images/resized/0004/6632/46632v1-max-250x250.jpg"],[[125,46],"assets/images/resized/0004/6632/46632v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.f2g.com/18_Aug_2008.htm","source_description":"F2G Ltd completes Â£6.3million financing round to fund pre-clinical and clinical development","raised_amount":6300000,"raised_currency_code":"GBP","funded_year":2008,"funded_month":8,"funded_day":18,"company":{"name":"F2G","permalink":"f2g","image":{"available_sizes":[[[134,140],"assets/images/resized/0005/0273/50273v1-max-150x150.png"],[[134,140],"assets/images/resized/0005/0273/50273v1-max-250x250.png"],[[134,140],"assets/images/resized/0005/0273/50273v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.fiercebiotech.com/press-releases/intradigm-corporation-closes-final-tranche-21-4-million-series-b-financing-philip-haw","source_description":"Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive","raised_amount":21400000,"raised_currency_code":"USD","funded_year":2009,"funded_month":1,"funded_day":7,"company":{"name":"Intradigm Corporation","permalink":"intradigm-corporation","image":{"available_sizes":[[[150,34],"assets/images/resized/0005/0666/50666v1-max-150x150.png"],[[250,56],"assets/images/resized/0005/0666/50666v1-max-250x250.png"],[[316,72],"assets/images/resized/0005/0666/50666v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.fiercebiotech.com/story/viamet-gets-big-pharma-support-18m-round/2009-07-07","source_description":"Viamet gets Big Pharma support in $18M round Read more: http://www.fiercebiotech.com/story/viamet-gets-big-pharma-support-18m-round/2009-07-07#ixzz0S4Hjz62O","raised_amount":18000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":7,"funded_day":7,"company":{"name":"Viamet Pharmaceuticals","permalink":"viamet-pharmaceuticals","image":{"available_sizes":[[[150,46],"assets/images/resized/0006/3580/63580v1-max-150x150.jpg"],[[250,77],"assets/images/resized/0006/3580/63580v1-max-250x250.jpg"],[[255,79],"assets/images/resized/0006/3580/63580v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.fiercebiotech.com/story/epizyme-pulls-32m-vc-capital-new-investors/2009-10-07?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB0#ixzz0TIDqj9B1","source_description":"Epizyme pulls in $32M in VC capital, new investors","raised_amount":32000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":10,"funded_day":7,"company":{"name":"Epizyme","permalink":"epizyme","image":{"available_sizes":[[[150,74],"assets/images/resized/0006/1969/61969v1-max-150x150.jpg"],[[250,124],"assets/images/resized/0006/1969/61969v1-max-250x250.jpg"],[[450,224],"assets/images/resized/0006/1969/61969v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.fatetherapeutics.com/pdf/20091116_PressRelease.pdf","source_description":"Fate Therapetucis","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":11,"funded_day":16,"company":{"name":"Fate Therapeutics","permalink":"fate-therapeutics","image":{"available_sizes":[[[150,26],"assets/images/resized/0006/6439/66439v1-max-150x150.png"],[[250,43],"assets/images/resized/0006/6439/66439v1-max-250x250.png"],[[450,79],"assets/images/resized/0006/6439/66439v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.lectustherapeutics.com/PR_13%20February%202006.html","source_description":"Lectus Therapeutics closes Series A funding round raising Â£8.2 million","raised_amount":8200000,"raised_currency_code":"GBP","funded_year":2006,"funded_month":2,"funded_day":13,"company":{"name":"Lectus Therapeutics","permalink":"lectus-therapeutics","image":{"available_sizes":[[[150,53],"assets/images/resized/0008/0510/80510v1-max-150x150.jpg"],[[183,65],"assets/images/resized/0008/0510/80510v1-max-250x250.jpg"],[[183,65],"assets/images/resized/0008/0510/80510v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"e","source_url":"http://onbiovc.com/nereus-pharmaceuticals-inc-series-e-20m/","source_description":"Nereus Pharmaceuticals, Inc.: Series E $20M","raised_amount":20000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":6,"funded_day":25,"company":{"name":"Nereus Pharmaceuticals","permalink":"nereus-pharmaceuticals","image":null}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.finsmes.com/2010/09/decimmune-therapeutics-receives-1m-in.html","source_description":"DecImmune Therapeutics Receives $1M in Equity Financing; $2.2M Phase II SBIR Funding","raised_amount":3200000,"raised_currency_code":"USD","funded_year":2010,"funded_month":9,"funded_day":27,"company":{"name":"DecImmune Therapeutics","permalink":"decimmune-therapeutics","image":null}}},{"funding_round":{"round_code":"b","source_url":"http://www.masshightech.com/stories/2011/07/11/daily35-Verastem-rounds-up-32M-in-second-funding.html","source_description":"Verastem rounds up $32M in second funding","raised_amount":32000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":7,"funded_day":14,"company":{"name":"Verastem","permalink":"verastem","image":{"available_sizes":[[[150,48],"assets/images/resized/0011/0535/110535v1-max-150x150.jpg"],[[250,80],"assets/images/resized/0011/0535/110535v1-max-250x250.jpg"],[[450,145],"assets/images/resized/0011/0535/110535v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.finsmes.com/2011/10/cleave-biosciences-raises-42m-series-financing.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29","source_description":"Cleave Biosciences Raises $42M in Series A Financing","raised_amount":42000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":10,"funded_day":11,"company":{"name":"Cleave Biosciences","permalink":"cleave-biosciences","image":null}}},{"funding_round":{"round_code":"b","source_url":"http://pevc.dowjones.com/article?an=DJFVW00020120605e865tt70p&from=alert&pid=32&ReturnUrl=http%3a%2f%2fpevc.dowjones.com%3a80%2farticle%3fan%3dDJFVW00020120605e865tt70p%26from%3dalert%26pid%3d32","source_description":"PhaseBio Pharmaceuticals Books $23M in Third Tranche of Series B ","raised_amount":23000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":6,"funded_day":5,"company":{"name":"PhaseBio Pharmaceuticals","permalink":"phasebio-pharmaceuticals","image":{"available_sizes":[[[150,49],"assets/images/resized/0007/2629/72629v1-max-150x150.jpg"],[[193,64],"assets/images/resized/0007/2629/72629v1-max-250x250.jpg"],[[193,64],"assets/images/resized/0007/2629/72629v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://www.fiercebiotech.com/press-releases/f2g-ltd-completes-30-million-financing-round-fund-pre-clinical-and-clinical","source_description":"F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":9,"funded_day":5,"company":{"name":"F2G","permalink":"f2g","image":{"available_sizes":[[[134,140],"assets/images/resized/0005/0273/50273v1-max-150x150.png"],[[134,140],"assets/images/resized/0005/0273/50273v1-max-250x250.png"],[[134,140],"assets/images/resized/0005/0273/50273v1-max-450x450.png"]],"attribution":null}}}}],"milestones":[],"providerships":[],"funds":[],"video_embeds":[],"external_links":[]}